Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chee Khoon Lee

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.
Future Oncology (London, England)|February 14, 2022
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancerRachel Woodford, Deborah Zhou, Sarah J Lord, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trialsDeborah Di-Xin Zhou, Sarah J Lord, Frank Po-Yen Lin, et al.
NPJ Precision Oncology|June 24, 2021
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologyFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.
JAMA Oncology|December 23, 2017
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
Future Oncology (London, England)|June 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST programDerrick H W Siu, Frank P Y Lin, David M Thomas, et al.
Therapeutic Advances in Medical Oncology|September 4, 2024
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation frameworkDoah Cho, Sarah J Lord, Robyn Ward, et al.
Springerplus|September 12, 2013
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneChee Khoon Lee, Val J Gebski, Alan S Coates, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2021
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysisPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.
Lung Cancer (Amsterdam, Netherlands)|December 8, 2024
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutationsMengzhao Wang, Yan Xu, Wen-Tsung Huang, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Cancer|January 5, 2022
The validity of progression-free survival 2 as a surrogate trial end point for overall survivalRachel G Woodford, Deborah D-X Zhou, Peey-Sei Kok, et al.
Future Oncology (London, England)|February 14, 2022
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancerRachel Woodford, Deborah Zhou, Sarah J Lord, et al.
Lung Cancer (Amsterdam, Netherlands)|January 7, 2026
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trialsDeborah Di-Xin Zhou, Sarah J Lord, Frank Po-Yen Lin, et al.
NPJ Precision Oncology|June 24, 2021
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncologyFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.
JAMA Oncology|December 23, 2017
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
Future Oncology (London, England)|June 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST programDerrick H W Siu, Frank P Y Lin, David M Thomas, et al.
Therapeutic Advances in Medical Oncology|September 4, 2024
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation frameworkDoah Cho, Sarah J Lord, Robyn Ward, et al.
Springerplus|September 12, 2013
Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneChee Khoon Lee, Val J Gebski, Alan S Coates, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2021
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysisPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.
Lung Cancer (Amsterdam, Netherlands)|December 8, 2024
Sunvozertinib monotherapy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer with EGFR mutationsMengzhao Wang, Yan Xu, Wen-Tsung Huang, et al.
Pageof 9